{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:22Z","timestamp":1786987582273,"version":"build-2736575974"},"reference-count":234,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006512","name":"Duke University Medical Center Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006512","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ctrv.2023.102651","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T04:42:55Z","timestamp":1699072975000},"page":"102651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Recent advances in genomics and therapeutics in mantle cell lymphoma"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-6728","authenticated-orcid":false,"given":"Tingxun","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna M.","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0005","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102651_b0010","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102651_b0015","series-title":"World Health Organization classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102651_b0020","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/cncr.34106","article-title":"Ofatumumab plus HyperCVAD\/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study","volume":"128","author":"Torka","year":"2022","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.ctrv.2023.102651_b0025","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-Cell Lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102651_b0030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11912-021-01094-y","article-title":"Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management","volume":"23","author":"Isaac","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11864-019-0684-8","article-title":"Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment","volume":"20","author":"Jain","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0040","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-020-00394-z","article-title":"Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma","volume":"11","author":"Castellino","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102651_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239740","article-title":"Mantle cell lymphoma with gastrointestinal involvement and the role of endoscopic examinations","volume":"15","author":"Lee","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102651_b0055","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102651_b0060","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3109\/10428194.2013.767454","article-title":"Risk factors of central nervous system relapse in mantle cell lymphoma","volume":"54","author":"Conconi","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"45","key":"10.1016\/j.ctrv.2023.102651_b0065","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102651_b0070","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.ctrv.2023.102651_b0075","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0080","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102651_b0085","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0090","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","article-title":"Molecular Pathogenesis of Mantle Cell Lymphoma","volume":"34","author":"Navarro","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"17","key":"10.1016\/j.ctrv.2023.102651_b0095","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102651_b0100","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210280","article-title":"NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications","volume":"24","author":"Deshotels","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0110","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102651_b0115","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3324\/haematol.2012.071340","article-title":"Immune evasion of mantle cell lymphoma: expression of B7\u2013H1 leads to inhibited T-cell response to and killing of tumor cells","volume":"98","author":"Wang","year":"2013","journal-title":"Haematologica"},{"issue":"5\u20136","key":"10.1016\/j.ctrv.2023.102651_b0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0125","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0135","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102651_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082120","article-title":"Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy","volume":"12","author":"Malarikova","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102651_b0145","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.clml.2023.04.004","article-title":"Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma","volume":"23","author":"Gaudio","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.ctrv.2023.102651_b0155","first-page":"8226","article-title":"The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival","volume":"63","author":"Mart\u00ednez","year":"2003","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.ctrv.2023.102651_b0160","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2008-07-170183","article-title":"Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling","volume":"113","author":"Be\u00e0","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102651_b0165","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","article-title":"Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways","volume":"130","author":"Rizzatti","year":"2005","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102651_b0170","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","article-title":"Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting","volume":"113","author":"Kurtova","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0175","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2006-11-060350","article-title":"Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas","volume":"110","author":"Lwin","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0180","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153283","article-title":"Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma","volume":"132","author":"Yi","year":"2022","journal-title":"J Clin Invest"},{"issue":"36","key":"10.1016\/j.ctrv.2023.102651_b0185","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.20.02287","article-title":"High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management","volume":"38","author":"Jain","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10044","key":"10.1016\/j.ctrv.2023.102651_b0190","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0195","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b0200","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102651_b0205","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102651_b0210","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ctrv.2023.102651_b0215","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0220","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/his.12760","article-title":"MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma","volume":"68","author":"Choe","year":"2016","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0225","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1046\/j.1365-2141.2003.04121.x","article-title":"Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma","volume":"120","author":"Nagy","year":"2003","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b0230","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0235","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/gcc.22123","article-title":"Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index","volume":"53","author":"Sarkozy","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b0240","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41379-021-00885-9","article-title":"EZH2 expression is associated with inferior overall survival in mantle cell lymphoma","volume":"34","author":"Martinez-Baquero","year":"2021","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102651_b0245","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102651_b0250","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b0255","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1158\/1078-0432.CCR-12-3077","article-title":"microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics","volume":"19","author":"Navarro","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.ctrv.2023.102651_b0260","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2012.45.3050","article-title":"MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma","volume":"31","author":"Goswami","year":"2013","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2023.102651_b0265","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2014-06-584193","article-title":"miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator","volume":"125","author":"Husby","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102651_b0270","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjh.12409","article-title":"Prognostic impact of monocyte count at presentation in mantle cell lymphoma","volume":"162","author":"von Hohenstaufen","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102651_b0275","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/bjh.12531","article-title":"Absolute monocyte count at diagnosis and survival in mantle cell lymphoma","volume":"163","author":"Porrata","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0280","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgo.2015.04.005","article-title":"Autologous hematopoietic stem cell transplantation in elderly patients (\u2265 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study","volume":"6","author":"Hermet","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2023.102651_b0285","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2021004765","article-title":"Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy","volume":"5","author":"Bond","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102651_b0290","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2023.102651_b0295","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","article-title":"Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102651_b0300","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","author":"Abrisqueta","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b0305","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/10428194.2018.1455973","article-title":"Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma","volume":"59","author":"Calzada","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b0310","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/bloodadvances.2022009225","article-title":"Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma","volume":"7","author":"Epperla","year":"2023","journal-title":"Blood Adv"},{"issue":"28","key":"10.1016\/j.ctrv.2023.102651_b0315","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0320","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102651_b0325","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2013.088377","volume":"98","author":"Arranz","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0330","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102651_b0335","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b0340","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.31361","article-title":"Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma","volume":"124","author":"Romaguera","year":"2018","journal-title":"Cancer"},{"issue":"36","key":"10.1016\/j.ctrv.2023.102651_b0345","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102651_b0350","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.beha.2012.04.003","article-title":"Autologous transplantation and management of younger patients with mantle cell lymphoma","volume":"25","author":"Geisler","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0355","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102651_b0360","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.ctrv.2023.102651_b0365","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0370","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/bloodadvances.2019001355","article-title":"Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma","volume":"4","author":"Merryman","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0375","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14480","article-title":"RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106","volume":"176","author":"Chen","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0380","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network","volume":"41","author":"Hermine","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0385","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","article-title":"Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2023.102651_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2022-163018","article-title":"Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0395","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0400","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102651_b0405","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/ijc.34412","article-title":"Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study","volume":"152","author":"Kotchetkov","year":"2023","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0410","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ctrv.2023.102651_b0415","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023009744","article-title":"Long term follow-up of Rituximab plus Bendamustine and Cytarabine (R-BAC) in elderly patients with newly diagnosed MCL","author":"Tisi","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b0420","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102651_b0425","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102651_b0430","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma","volume":"128","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102651_b0435","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102651_b0440","doi-asserted-by":"crossref","unstructured":"Smith MR, Jegede O, Martin P, Till BG, Parekh SS, Yang DT, Kostakoglu L, Casulo C, Bartlett NL, Caimi PF et al. ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) \u00b1 lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS. Journal of Clinical Oncology 2021, 39(15_suppl):7503-7503.","DOI":"10.1200\/JCO.2021.39.15_suppl.7503"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102651_b0445","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102651_b0450","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b0455","first-page":"1196","article-title":"Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm","volume":"40","author":"Gin\u00e9","year":"2022","journal-title":"Phase II Trial J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2023.102651_b0460","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102651_b0465","doi-asserted-by":"crossref","unstructured":"Phillips TJ, Danilov AV, Bond DA, Herrera AF, Maddocks KJ, Devata S, Karimi Y, Carty S, Wilcox RA, Kaminski MS et al. The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability. Journal of Clinical Oncology 2021, 39(15_suppl):7505-7505.","DOI":"10.1200\/JCO.2021.39.15_suppl.7505"},{"key":"10.1016\/j.ctrv.2023.102651_b0470","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023009992","article-title":"Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma","author":"Phillips","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2023.102651_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103212","article-title":"Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review","volume":"158","author":"Monga","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102651_b0480","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","article-title":"High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience","volume":"22","author":"Milpied","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0485","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission","volume":"16","author":"Freedman","year":"1998","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b0490","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0495","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1702135","article-title":"Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study","volume":"25","author":"Decaudin","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0500","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102651_b0505","doi-asserted-by":"crossref","unstructured":"Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113(18):4144-4152.","DOI":"10.1182\/blood-2008-10-184200"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102651_b0510","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102651_b0515","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(21)00195-2","article-title":"Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial","volume":"8","author":"Zoellner","year":"2021","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b0520","first-page":"911.e911","article-title":"Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma","volume":"27","author":"Riedell","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0525","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0530","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.clml.2017.11.002","article-title":"Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience","volume":"18","author":"Sawalha","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0535","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102651_b0540","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0545","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3324\/haematol.2021.279037","article-title":"Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007\u20132017","volume":"107","author":"Albertsson-Lindblad","year":"2022","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.ctrv.2023.102651_b0550","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ctrv.2023.102651_b0555","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1182\/bloodadvances.2020002068","article-title":"Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma","volume":"4","author":"Villa","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b0560","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.3109\/10428194.2015.1028055","article-title":"Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study","volume":"56","author":"Schreiber","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.ctrv.2023.102651_b0565","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood.V124.21.149.149","article-title":"Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601","volume":"124","author":"Till","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102651_b0570","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","author":"McCulloch","year":"2020","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.ctrv.2023.102651_b0575","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236089","article-title":"Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma","volume":"13","author":"Bega","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0580","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.ctrv.2023.102651_b0585","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0590","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0595","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0600","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ctrv.2023.102651_b0605","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0610","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102651_b0615","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/bjh.17363","article-title":"Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients","volume":"193","author":"McCulloch","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0620","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0625","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0630","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102651_b0635","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/oncolo\/oyac260","article-title":"Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies","volume":"28","author":"Mu\u00f1oz","year":"2023","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0640","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"10121","key":"10.1016\/j.ctrv.2023.102651_b0645","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ctrv.2023.102651_b0650","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"10277","key":"10.1016\/j.ctrv.2023.102651_b0655","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b0660","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0665","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood-2017-09-807230","article-title":"Composite morphologically and immunohistochemically distinct classical and pleomorphic mantle cell lymphomas","volume":"131","author":"Wang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102651_b0670","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2022.282469","article-title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","author":"Le Gouill","year":"2023","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.ctrv.2023.102651_b0675","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2023.102651_b0680","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2021-148544","article-title":"Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed\/Refractory B-Cell Malignancies","volume":"138","author":"Shadman","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0685","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b0690","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0695","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102651_b0700","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \u201creal world\u201d study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b0705","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle Cell Lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0710","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.15108","article-title":"Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects","volume":"181","author":"Hershkovitz-Rokah","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102651_b0715","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102651_b0720","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br J Haematol"},{"issue":"491","key":"10.1016\/j.ctrv.2023.102651_b0725","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"issue":"45","key":"10.1016\/j.ctrv.2023.102651_b0730","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2023.102651_b0735","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7570","article-title":"Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial","volume":"34","author":"Lenz","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0740","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-023-01496-4","article-title":"Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents","volume":"16","author":"Jain","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0745","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2023.102651_b0750","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023020211","article-title":"CARD11 gain of function upregulates BCL2A1 and promotes resistance to targeted therapies combination in B-cell lymphoma","author":"Decombis","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102651_b0755","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study","author":"Hess","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102651_b0760","article-title":"Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2023.102651_b0765","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.18632\/oncotarget.24310","article-title":"First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL","volume":"9","author":"Byrd","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0770","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12030376","article-title":"Relapsed\/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors","volume":"12","author":"Burkart","year":"2022","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102651_b0775","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0780","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.25796","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0785","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13045-021-01188-x","article-title":"Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2023.102651_b0790","doi-asserted-by":"crossref","unstructured":"Handunnetti SM, Anderson MA, Burbury K, Hicks RJ, Birbirsa B, Bressel M, Di Iulio J, Westerman DA, Lade S, Agarwal R et al. Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. Blood 2019, 134(Supplement_1):756-756.","DOI":"10.1182\/blood-2019-126619"},{"issue":"13","key":"10.1016\/j.ctrv.2023.102651_b0795","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0800","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.2022.282031","article-title":"Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma","volume":"108","author":"Liu","year":"2023","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2023.102651_b0805","first-page":"36","article-title":"Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed\/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial","volume":"136","author":"Jerkeman","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0810","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0815","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.15107","article-title":"A phase II study of carfilzomib in the treatment of relapsed\/refractory mantle cell lymphoma","volume":"184","author":"Lee","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0820","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.2021013326","article-title":"Therapeutic options for relapsed\/refractory mantle cell lymphoma","volume":"139","author":"Eyre","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2023.102651_b0825","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102651_b0830","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/bjh.12780","article-title":"Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study","volume":"165","author":"Wang","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102651_b0835","first-page":"1433","article-title":"Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells","volume":"90","author":"Hipp","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102651_b0840","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.ctrv.2023.102651_b0845","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2023.102651_b0850","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0855","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0860","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1158\/1078-0432.CCR-15-3135","article-title":"Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma","volume":"23","author":"Yang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102651_b0865","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/13543776.2020.1725470","article-title":"Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)","volume":"30","author":"Zhao","year":"2020","journal-title":"Expert Opin Ther Pat"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102651_b0870","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.tplants.2015.07.005","article-title":"Histone Acetylation Enzymes Coordinate Metabolism and Gene Expression","volume":"20","author":"Shen","year":"2015","journal-title":"Trends Plant Sci"},{"issue":"7360","key":"10.1016\/j.ctrv.2023.102651_b0875","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b0880","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/s41388-018-0550-3","article-title":"Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma","volume":"38","author":"Guo","year":"2019","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0885","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1080\/10428194.2018.1520986","article-title":"A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib","volume":"60","author":"Chaturvedi","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102651_b0890","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2018.05.023","article-title":"Strair R et al.: A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma","volume":"18","author":"Yazbeck","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0895","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A Phase I\/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed\/Refractory Lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.ctrv.2023.102651_b0900","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b0905","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0910","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3324\/haematol.2019.224535","article-title":"Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study","volume":"106","author":"Morschhauser","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2023.102651_b0915","doi-asserted-by":"crossref","unstructured":"Keats JA, Lee A, Cunniff JC, Chen W, Mehovic R, Estanek V, Markwood C, Tang C, Dransfield DT, Gibaja V et al. Abstract 1161: EZH2 inhibitor tazemetostat demonstrates activity in preclinical models of Bruton's tyrosine kinase inhibitor-resistant relapsed\/refractory mantle cell lymphoma. Cancer Research 2021, 81(13_Supplement):1161-1161.","DOI":"10.1158\/1538-7445.AM2021-1161"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b0920","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102651_b0925","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102238","article-title":"A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells","volume":"14","author":"Ghaderi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ctrv.2023.102651_b0930","doi-asserted-by":"crossref","unstructured":"Sloan S, Brown F, Chung JH, Prouty A, Wheeler E, Harrington BK, Brooks E, Yilmaz AS, Ozer HG, Byrd JC et al. Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma. Blood 2019, 134(Supplement_1):4065-4065.","DOI":"10.1182\/blood-2019-128998"},{"issue":"20","key":"10.1016\/j.ctrv.2023.102651_b0935","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood-2018-02-832535","article-title":"SOX11 augments BCR signaling to drive MCL-like tumor development","volume":"131","author":"Kuo","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ctrv.2023.102651_b0940","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-20-5039","article-title":"SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma","volume":"27","author":"Jatiani","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.ctrv.2023.102651_b0945","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","article-title":"Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia","volume":"125","author":"Hing","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102651_b0950","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13543784.2020.1760245","article-title":"Novel agents for mantle cell lymphoma: molecular rational and clinical data","volume":"29","author":"Sarkozy","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"29","key":"10.1016\/j.ctrv.2023.102651_b0955","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b0960","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102651_b0965","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102651_b0970","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b0975","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.3324\/haematol.2016.154211","article-title":"Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi","volume":"102","author":"Zaja","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102651_b0980","first-page":"793","article-title":"Lenalidomide plus Rituximab for Mantle-Cell Lymphoma","volume":"374","author":"Ruan","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0985","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40164-023-00432-z","article-title":"The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"12","author":"Lu","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102651_b0990","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b0995","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evidence"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2023.102651_b1000","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood-2022-167153","article-title":"Phase 1\/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102651_b1005","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2023.102651_b1010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2021-148949","article-title":"Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R\/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy","volume":"138","author":"Phillips","year":"2021","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ctrv.2023.102651_b1015","doi-asserted-by":"crossref","DOI":"10.3390\/cells11172747","article-title":"Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma","volume":"11","author":"Heini","year":"2022","journal-title":"Cells"},{"issue":"10306","key":"10.1016\/j.ctrv.2023.102651_b1020","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2023.102651_b1025","doi-asserted-by":"crossref","unstructured":"Clausen MR, Lugtenburg P, Hutchings M, Johnson PWM, Linton KM, Lewis DJ, Chamuleau M, Balari AS, Cunningham D, Elliott B et al. Subcutaneous epcoritamab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity. Journal of Clinical Oncology 2021, 39(15_suppl):7518-7518.","DOI":"10.1200\/JCO.2021.39.15_suppl.7518"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b1030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2023.102651_b1035","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b1040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b1045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b1050","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b1055","first-page":"3382","article-title":"Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma","volume":"17","author":"Yang","year":"2019","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102651_b1060","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1080\/10428194.2019.1569231","article-title":"Modulation of immune checkpoint molecule expression in mantle cell lymphoma","volume":"60","author":"Harrington","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b1065","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1186\/s12885-022-09803-x","article-title":"Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma","volume":"22","author":"Ameli","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102651_b1070","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102651_b1075","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2023.102651_b1080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-136158","article-title":"Safety and Preliminary Efficacy in Patients with Relapsed\/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001","volume":"136","author":"Palomba","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102651_b1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106742","article-title":"Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data","volume":"190","author":"Zinzi","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ctrv.2023.102651_b1090","doi-asserted-by":"crossref","first-page":"1122329","DOI":"10.3389\/fonc.2023.1122329","article-title":"Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy","volume":"13","author":"Lipe","year":"2023","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102651_b1095","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102651_b1100","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00259-022-06075-2","article-title":"Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy","volume":"50","author":"Winkelmann","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2023.102651_b1105","article-title":"Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy","author":"Yan","year":"2023","journal-title":"Front Med"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2023.102651_b1110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood-2022-160459","article-title":"Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study","volume":"140","author":"Minson","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2023.102651_b1115","first-page":"11:608167","article-title":"Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102651_b1120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102651_b1125","first-page":"1","article-title":"Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease","author":"Lew","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b1130","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halldorsdottir","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102651_b1135","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","article-title":"Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3","volume":"5","author":"Eskelund","year":"2021","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102651_b1140","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/ajh.27044","article-title":"Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy","volume":"98","author":"Karolov\u00e1","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2023.102651_b1145","doi-asserted-by":"crossref","unstructured":"Shah N, Castillo-Tokumori F, Chavez JC, Isenalumhe L, Saeed H, Bello C, Sokol L, Pinilla Ibarz J, Shah B. Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience. Blood 2019, 134(Supplement_1):3991-3991.","DOI":"10.1182\/blood-2019-127291"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b1150","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.3324\/haematol.2018.194399","article-title":"Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma","volume":"103","author":"Eskelund","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102651_b1155","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102651_b1160","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ctrv.2023.102651_b1165","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","article-title":"Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102651_b1170","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1038\/s41409-021-01418-3","article-title":"T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease","volume":"56","author":"Lew","year":"2021","journal-title":"Bone Marrow Transplant"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:30:09Z","timestamp":1759656609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223001445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":234,"alternative-id":["S0305737223001445"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102651","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in genomics and therapeutics in mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102651"}}